<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04001023</url>
  </required_header>
  <id_info>
    <org_study_id>15867</org_study_id>
    <nct_id>NCT04001023</nct_id>
  </id_info>
  <brief_title>Overcoming Chemoresistance in Advanced Ovarian Cancer Via Targeting Hypoxia</brief_title>
  <acronym>OVANOX</acronym>
  <official_title>Overcoming Chemoresistance in Advanced Ovarian Cancer Via Targeting Hypoxia</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Turku University Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Turku University Hospital</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The goal of this non-randomized prospective study is to use 18F-EF5-PET/CT imaging to
      identify and locate intraabdominal hypoxic ovarian cancer lesions. With targeted surgical
      sampling, precisely obtain hypoxic and potentially chemoresistant cancer tissue for our
      analyses and identify key molecular differences between hypoxic and non-hypoxic tumors within
      the same patient.

      A portion of advanced stage EOC are inoperable at diagnosis and can be treated with
      neoadjuvant chemotherapy (NACT) before surgery. This approach offers a unique opportunity to
      study how hypoxic tumor areas respond to treatment.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      MORE SPECIFIC AIMS

        1. To validate the feasibility of PET-tracer EF5 in EOC imaging.

             -  Quantify the amount and exact locations of hypoxic tumors in EOC patients using
                herein developed protocol and tracers (18F-EF5 and 18F-FDG) in diagnostic and
                neoadjuvant settings.

             -  Measure the non-cancer related EF5 accumulation spots and establish the potential
                pitfalls in abdominal EF5 imaging

             -  Establish a method to verify hypoxic locations with 18F-EF5-PET/CT information
                during the operation.

             -  Develop and validate a model that predicts chemotherapy response based on
                functional imaging information.

        2. To reveal hypoxia related alterations in collected tissue samples (i.e. altered DNA
           damage repair, altered mitochondrial respiratory functioning, overexpression of hypoxia
           response elements etc)
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">March 9, 2017</start_date>
  <completion_date type="Anticipated">December 31, 2025</completion_date>
  <primary_completion_date type="Anticipated">December 31, 2022</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>18F-EF5 maximum standardized uptake values (SUVmax)</measure>
    <time_frame>2-3 years</time_frame>
    <description>Tumor and musculus gluteus maximus SUVmax ratio ≥1.5 is considered to refer to hypoxia</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Correlation between the uptake of 18F-EF5 isotope in PET/CT and immunohistochemical profile of tumor tissue</measure>
    <time_frame>2-3 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Disease-free survival</measure>
    <time_frame>5 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall survival</measure>
    <time_frame>5 years</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">40</enrollment>
  <condition>Epithelial Ovarian Cancer</condition>
  <condition>Fallopian Tube Cancer</condition>
  <condition>Peritoneal Carcinoma</condition>
  <condition>Hypoxia</condition>
  <arm_group>
    <arm_group_label>PDS</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>18F-EF5 PET/CT and 18F-FDG PET/CT scan prior to primary cytoreductive surgery and targeted sample collection during primary cytoreductive surgery</description>
  </arm_group>
  <arm_group>
    <arm_group_label>IDS</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>18F-EF5 PET/CT and 18F-FDG PET/CT scans prior to diagnostic laparoscopy and after neoadjuvant chemotherapy before interval cytoreductive surgery .
Targeted sample collection during diagnostic laparoscopy and interval cytoreductive surgery</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Imaging with 18F-EF5 PET/CT</intervention_name>
    <description>Both 18F-FDG PET/CT and 18F-EF5 PET/CT imaging are performed in 1) preoperative work-up to clarify the disease distribution, 2) before IDS to evaluate treatment response to NACT (IDS arm); targeted samples from hypoxic and non-hypoxic tumors are collected during surgery</description>
    <arm_group_label>IDS</arm_group_label>
    <arm_group_label>PDS</arm_group_label>
    <other_name>Collection of targeted samples during surgery</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  newly diagnosed advanced epithelial ovarian, primary peritoneal or fallopian tube
             cancer.

          -  age 18-79 years

          -  informed concent

        Exclusion Criteria:

          -  previous cancer

          -  pregnancy or nursing
      </textblock>
    </criteria>
    <gender>Female</gender>
    <gender_based>Yes</gender_based>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>79 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Maren Laasik, MD</last_name>
    <phone>+35823130000</phone>
    <email>maren.laasik@utu.fi</email>
  </overall_contact>
  <location>
    <facility>
      <name>Turku University hospital</name>
      <address>
        <city>Turku</city>
        <zip>20521</zip>
        <country>Finland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sakari Hietanen, MD, PhD, Adj. prof</last_name>
      <phone>+35823130000</phone>
      <email>sakari.hietanen@tyks.fi</email>
    </contact>
    <investigator>
      <last_name>Johanna Hynninen, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Marko Seppänen, MD, PhD, Adj. prof.</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Maren Laasik, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Sakari Hietanen, MD, PhD, Adj. pr</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Finland</country>
  </location_countries>
  <verification_date>August 2019</verification_date>
  <study_first_submitted>January 11, 2019</study_first_submitted>
  <study_first_submitted_qc>June 26, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">June 27, 2019</study_first_posted>
  <last_update_submitted>August 5, 2019</last_update_submitted>
  <last_update_submitted_qc>August 5, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">August 7, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>advanced ovarian cancer</keyword>
  <keyword>EF5-PET/CT</keyword>
  <keyword>hypoxia</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ovarian Neoplasms</mesh_term>
    <mesh_term>Carcinoma, Ovarian Epithelial</mesh_term>
    <mesh_term>Fallopian Tube Neoplasms</mesh_term>
    <mesh_term>Hypoxia</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

